Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome
Yannick Cyr, Valérie Lamantia, Simon Bissonnette, Melanie Burnette, Aurèle Besse-Patin, Annie Demers, Martin Wabitsch, Michel Chrétien, Gaétan Mayer, Jennifer L Estall, Maya Saleh, May Faraj, Yannick Cyr, Valérie Lamantia, Simon Bissonnette, Melanie Burnette, Aurèle Besse-Patin, Annie Demers, Martin Wabitsch, Michel Chrétien, Gaétan Mayer, Jennifer L Estall, Maya Saleh, May Faraj
Abstract
Background: LDL-cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflammasome/interleukin-1 beta (IL-1β) pathway promotes white adipose tissue (WAT) dysfunction and type 2 diabetes (T2D) and is regulated by LDL receptors (LDLR and CD36). We hypothesized that: (a) normocholesterolemic subjects with lower plasma PCSK9, identifying those with higher WAT surface-expression of LDLR and CD36, have higher activation of WAT NLRP3 inflammasome and T2D risk factors, and; (b) LDL upregulate adipocyte NLRP3 inflammasome and inhibit adipocyte function.
Methodology: Post hoc analysis was conducted in 27 overweight/ obese subjects with normal plasma LDL-C and measures of disposition index (DI during Botnia clamps) and postprandial fat metabolism. WAT was assessed for surface-expression of LDLR and CD36 (immunohistochemistry), protein expression (immunoblot), IL-1β secretion (AlphaLISA), and function (3 H-triolein storage).
Results: Compared to subjects with higher than median plasma PCSK9, subjects with lower PCSK9 had higher WAT surface-expression of LDLR (+81%) and CD36 (+36%), WAT IL-1β secretion (+284%), plasma IL-1 receptor-antagonist (+85%), and postprandial hypertriglyceridemia, and lower WAT pro-IL-1β protein (-66%), WAT function (-62%), and DI (-28%), without group-differences in body composition, energy intake or expenditure. Adjusting for WAT LDLR or CD36 eliminated group-differences in WAT function, DI, and postprandial hypertriglyceridemia. Native LDL inhibited Simpson-Golabi Behmel-syndrome (SGBS) adipocyte differentiation and function and increased inflammation.
Conclusion: Normocholesterolemic subjects with lower plasma PCSK9 and higher WAT surface-expression of LDLR and CD36 have higher WAT NLRP3 inflammasome activation and T2D risk factors. This may be due to LDL-induced inhibition of adipocyte function.
Keywords: adipose tissue and systemic inflammation; apoB-lipoproteins; cardiometabolic risk; plasma apoB-to-PCSK9.
Conflict of interest statement
The authors declare no conflict of interest associated with this manuscript.
© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.
Figures
References
- Arner, E. , Westermark, P. O. , Spalding, K. L. , Britton, T. , Ryden, M. , Frisen, J. , Bernard, S. , & Arner, P. (2010). Adipocyte turnover: Relevance to human adipose tissue morphology. Diabetes, 59, 105–109.
- Bissonnette, S. , Lamantia, V. , Cyr, Y. , Provost, V. , Devaux, M. , & Faraj, M. (2018). Native LDL are priming signals for the NLRP3 inflammasome in human white adipose tissue. International Symposium on Atherosclerosis.Atherosclerosis Supplements.
- Bissonnette, S. , Saint‐Pierre, N. , Lamantia, V. , Cyr, Y. , Wassef, H. , & Faraj, M. (2015). Plasma IL‐1Ra: linking hyperapoB to risk factors for type 2 diabetes independent of obesity in humans. Nutr Diabetes, 5, e180.
- Bissonnette, S. , Saint‐Pierre, N. , Lamantia, V. , Leroux, C. , Provost, V. , Cyr, Y. , Rabasa‐Lhoret, R. , & Faraj, M. (2018). High plasma apolipoprotein B identifies obese subjects who best ameliorate white adipose tissue dysfunction and glucose‐induced hyperinsulinemia after a hypocaloric diet. The American Journal of Clinical Nutrition, 108, 62–76.
- Bissonnette, S. , Salem, H. , Wassef, H. , Saint‐Pierre, N. , Tardif, A. , Baass, A. , Dufour, R. , & Faraj, M. (2013). Low density lipoprotein delays clearance of triglyceride‐rich lipoprotein by human subcutaneous adipose tissue. Journal of Lipid Research, 54, 1466–1476.
- Calvo, D. , Gómez‐Coronado, D. , Suárez, Y. , Lasunción, M. A. , & Vega, M. A. (1998). Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. Journal of Lipid Research, 39, 777–788.
- Cavelti‐Weder, C. , Babians‐Brunner, A. , Keller, C. , Stahel, M. A. , Kurz‐Levin, M. , Zayed, H. , Solinger, A. M. , Mandrup‐Poulsen, T. , Dinarello, C. A. , & Donath, M. Y. (2012). Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care, 35, 1654–1662.
- Connelly, P. W. , Poapst, M. , Davignon, J. , Lussier‐Cacan, S. , Reeder, B. , Lessard, R. , Hegele, R. A. , & Csima, A. (1999). Reference values of plasma apolipoproteins A‐I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group. Canadian Journal of Cardiology, 15, 409–418.
- Corrao, G. , Ibrahim, B. , Nicotra, F. , Soranna, D. , Merlino, L. , Catapano, A. L. , Tragni, E. , Casula, M. , Grassi, G. , & Mancia, G. (2014). Statins and the risk of diabetes: Evidence from a large population‐based cohort study. Diabetes Care, 37, 2225–2232.
- Cyr, Y. , Bissonnette, S. , Lamantia, V. , Wassef, H. , Loizon, E. , NGO Sock, E. T. , Vidal, H. , Mayer, G. , Chretien, M. , & Faraj, M. (2020). White adipose tissue surface expression of LDLR and CD36 is associated with risk factors for type 2 diabetes in adults with obesity. Obesity (Silver Spring), 28, 2357–2367.
- Cyr, Y. , Wassef, H. , Bissonnette, S. , Lamantia, V. , Davignon, J. , & Faraj, M. (2016). White adipose tissue apoC‐I secretion; role in delayed chylomicron clearance in vivo and ex vivo in white adipose tissue in obese subjects. Journal of Lipid Research, 57, 1074–1085.
- Demers, A. , Samami, S. , Lauzier, B. , Des rosiers, C. , Sock, E. T. N. , Ong, H. , & Mayer, G. (2015). PCSK9 induces CD36 degradation and affects long‐chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 2517–2525.
- Dubuc, G. , Chamberland, A. , Wassef, H. , Davignon, J. , Seidah, N. G. , Bernier, L. , & Prat, A. (2004). Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis‐regulated convertase‐1 implicated in familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1454–1459.
- Faraj, M. (2020). LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue. J Biomed Res, 34, 251–259.
- Faraj, M. , Sniderman, A. , & Cianflone, K. (2004). ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. Journal of Lipid Research, 45, 657–666.
- Ference, B. A. , Robinson, J. G. , Brook, R. D. , Catapano, A. L. , Chapman, M. J. , Neff, D. R. , Voros, S. , Giugliano, R. P. , Davey Smith, G. , Fazio, S. , & Sabatine, M. S. (2016). Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. New England Journal of Medicine, 375, 2144–2153.
- Fischer‐Posovszky, P. , Newell, F. S. , Wabitsch, M. , & Tornqvist, H. E. (2008). Human SGBS cells ‐ a unique tool for studies of human fat cell biology. Obesity Facts, 1, 184–189.
- Gastaldelli, A. , Gaggini, M. , & Defronzo, R. A. (2017). Role of adipose tissue insulin resistance in the natural history of T2DM: Results from the San Antonio metabolism study. Diabetes, 66(4), 815–822.
- Glatz, J. F. C. , & Luiken, J. J. F. P. (2018). Dynamic role of the transmembrane glycoprotein CD36 (SR‐B2) in cellular fatty acid uptake and utilization. Journal of Lipid Research, 59(7), 1084–1093. 10.1194/jlr.R082933
- Hamm, J. K. , Park, B. H. , & Farmer, S. R. (2001). A role for C/EBPbeta in regulating peroxisome proliferator‐activated receptor gamma activity during adipogenesis in 3T3‐L1 preadipocytes. Journal of Biological Chemistry, 276, 18464–18471.
- Koenen, T. B. , Stienstra, R. , van Tits, L. J. , Joosten, L. A. B. , van Velzen, J. F. , Hijmans, A. , Pol, J. A. , van der Vliet, J. A. , Netea, M. G. , Tack, C. J. , Stalenhoef, A. F. H. , & de Graaf, J. (2011). The inflammasome and caspase‐1 activation: A new mechanism underlying increased inflammatory activity in human visceral adipose tissue. Endocrinology, 152(10), 3769–3778.
- Lamantia, V. , Bissonnette, S. , Provost, V. , Devaux, M. , Cyr, Y. , Daneault, C. , Rosiers, C. D. , & Faraj, M. (2019). The association of polyunsaturated fatty acid delta‐5‐desaturase activity with risk factors for type 2 Diabetes Is Dependent On Plasma ApoB‐lipoproteins in overweight and obese adults. Journal of Nutrition, 149, 57–67.
- Lamantia, V. , Bissonnette, S. , Wassef, H. , Cyr, Y. , Baass, A. , Dufour, R. , Rabasa‐Lhoret, R. , & Faraj, M. (2017). ApoB‐lipoproteins and dysfunctional white adipose tissue; Relation to risk factors for type 2 diabetes in humans. Journal of Clinical Lipidology, 11, 34–45.
- Larsen, C. M. , Faulenbach, M. , Vaag, A. , Volund, A. , Ehses, J. A. , Seifert, B. , Mandrup‐Poulsen, T. , & Donath, M. Y. (2007). Interleukin‐1B receptor antagonist in type 2 diabetes mellitus. New England Journal of Medicine, 356, 1517–1526.
- Lefterova, M. I. , Zhang, Y. , Steger, D. J. , Schupp, M. , Schug, J. , Cristancho, A. , Feng, D. , Zhuo, D. , Stoeckert Jr, C. J. , Liu, X. S. , & Lazar, M. A. (2008). PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome‐wide scale. Genes & Development, 22, 2941–2952.
- Lorenzo, C. , Wagenknecht, L. E. , Rewers, M. J. , Karter, A. J. , Bergman, R. N. , Hanley, A. J. G. , & Haffner, S. M. (2010). Disposition index, glucose effectiveness, and conversion to type 2 diabetes: The Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care, 33, 2098–2103.
- Lotta, L. A. , Sharp, S. J. , Burgess, S. , Perry, J. R. B. , Stewart, I. D. , Willems, S. M. , Luan, J. A. , Ardanaz, E. , Arriola, L. , Balkau, B. , Boeing, H. , Deloukas, P. , Forouhi, N. G. , Franks, P. W. , Grioni, S. , Kaaks, R. , Key, T. J. , Navarro, C. , Nilsson, P. M. , … Wareham, N. J. (2016). Association between LDL‐cholesterol lowering genetic variants and risk of type 2 diabetes. JAMA, 316, 1383–1391.
- Mascitelli, L. , & Goldstein, M. R. (2018). Questioning the safety and benefits of evolocumab. The Lancet Diabetes & Endocrinology, 6, 11.
- Medina‐Gomez, G. , Gray, S. , & Vidal‐Puig, A. (2007). Adipogenesis and lipotoxicity: role of peroxisome proliferator‐activated receptor gamma (PPARgamma) and PPARgammacoactivator‐1 (PGC1). Public Health Nutrition, 10, 1132–1137.
- Murphy, R. M. , & Lamb, G. D. (2013). Important considerations for protein analyses using antibody based techniques: down‐sizing Western blotting up‐sizes outcomes. Journal of Physiology, 591, 5823–5831.
- Preiss, D. , & Sattar, N. (2015). Does the LDL receptor play a role in the risk of developing type 2 diabetes? JAMA, 313, 1016–1017.
- Rampanelli, E. , Orso, E. , Ochodnicky, P. , Liebisch, G. , Bakker, P. J. , Claessen, N. , Butter, L. M. , van den Bergh Weerman, M. A. , Florquin, S. , Schmitz, G. , & Leemans, J. C. (2017). Metabolic injury‐induced NLRP3 inflammasome activation dampens phospholipid degradation. Scientific Reports, 7, 2861.
- Ray, K. K. , Colhoun, H. M. , Szarek, M. , Baccara‐Dinet, M. , Bhatt, D. L. , Bittner, V. A. , Budaj, A. J. , Diaz, R. , Goodman, S. G. , Hanotin, C. , Harrington, R. A. , Jukema, J. W. , Loizeau, V. , Lopes, R. D. , Moryusef, A. , Murin, J. , Pordy, R. , Ristic, A. D. , Roe, M. T. , … INVESTIGATORS . (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol, 7, 618–628.
- Ridker, P. M. , Pradhan, A. , Macfadyen, J. , Libby, P. , & Glynn, R. J. (2012). Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. The Lancet, 380, 565–571.
- Sabatine, M. S. , Leiter, L. A. , Wiviott, S. D. , Giugliano, R. P. , Deedwania, P. , de Ferrari, G. M. , Murphy, S. A. , Kuder, J. F. , Gouni‐Berthold, I. , Lewis, B. S. , Handelsman, Y. , Pineda, A. L. , Honarpour, N. , Keech, A. C. , Sever, P. S. , & Pedersen, T. R. (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new‐onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The Lancet Diabetes & Endocrinology, 5, 941–950.
- Sattar, N. , Preiss, D. , Murray, H. M. , Welsh, P. , Buckley, B. M. , de Craen, A. J. M. , Seshasai, S. R. K. , McMurray, J. J. , Freeman, D. J. , Jukema, J. W. , Macfarlane, P. W. , Packard, C. J. , Stott, D. J. , Westendorp, R. G. , Shepherd, J. , Davis, B. R. , Pressel, S. L. , Marchioli, R. , Marfisi, R. M. , … Ford, I. (2010). Statins and risk of incident diabetes: a collaborative meta‐analysis of randomised statin trials. The Lancet, 375, 735–742.
- Sauer, S. , (2015). Ligands for the nuclear peroxisome proliferator‐activated receptor gamma. Trends in Pharmacological Sciences, 36, 688–704.
- Schmidt, A. F. , Swerdlow, D. I. , Holmes, M. V. , Patel, R. S. , Fairhurst‐Hunter, Z. , Lyall, D. M. , Hartwig, F. P. , Horta, B. L. , Hyppönen, E. , Power, C. , Moldovan, M. , van Iperen, E. , Hovingh, G. K. , Demuth, I. , Norman, K. , Steinhagen‐Thiessen, E. , Demuth, J. , Bertram, L. , Liu, T. , … Völker, U. et al (2016). PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study. The Lancet Diabetes & Endocrinology, 5, 97–105.
- Schmidt, R. J. , Beyer, T. P. , Bensch, W. R. , Qian, Y. W. , Lin, A. , Kowala, M. , Alborn, W. E. , Konrad, R. J. , & Cao, G. (2008). Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low‐density lipoprotein receptors in vivo. Biochemical and Biophysical Research Communications, 370, 634–640.
- Sheedy, F. J. , Grebe, A. , Rayner, K. J. , Kalantari, P. , Ramkhelawon, B. , Carpenter, S. B. , Becker, C. E. , Ediriweera, H. N. , Mullick, A. E. , Golenbock, D. T. , Stuart, L. M. , Latz, E. , Fitzgerald, K. A. , & Moore, K. J. (2013). CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nature Immunology, 14, 812–820.
- Skeldon, A. M. , Faraj, M. , & Saleh, M. (2014). Caspases and inflammasomes in metabolic inflammation. Immunology and Cell Biology, 92, 304–313.
- Sloan‐Lancaster, J. , Abu‐Raddad, E. , Polzer, J. , Miller, J. W. , Scherer, J. C. , de Gaetano, A. , Berg, J. K. , & Landschulz, W. H. (2013). Double‐blind, randomized study evaluating the glycemic and anti‐inflammatory effects of subcutaneous LY2189102, a neutralizing IL‐1β antibody, in patients with type 2 diabetes. Diabetes Care, 36, 2239–2246.
- Stienstra, R. , Joosten, L. A. B. , Koenen, T. , van Tits, B. , van Diepen, J. A. , van den Berg, S. A. A. , Rensen, P. C. N. , Voshol, P. J. , Fantuzzi, G. , Hijmans, A. , Kersten, S. , Müller, M. , van den Berg, W. B. , van Rooijen, N. , Wabitsch, M. , Kullberg, B. J. , van der Meer, J. W. M. , Kanneganti, T. , Tack, C. J. , & Netea, M. G. (2010). The inflammasome‐mediated caspase‐1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metabolism, 12, 593–605.
- Swanson, K. V. , Deng, M. , & Ting, J. P. (2019). The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nature Reviews Immunology, 19, 477–489.
- Swerdlow, D. I. , Preiss, D. , Kuchenbaecker, K. B. , Holmes, M. V. , Engmann, J. E. L. , Shah, T. , Sofat, R. , Stender, S. , Johnson, P. C. D. , Scott, R. A. , Leusink, M. , Verweij, N. , Sharp, S. J. , Guo, Y. , Giambartolomei, C. , Chung, C. , Peasey, A. , Amuzu, A. , Li, K. , …, Delaney, J. A. et al (2015). HMG‐coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet, 385, 351–361.
- Vandanmagsar, B. , Youm, Y. H. , Ravussin, A. , Galgani, J. E. , Stadler, K. , Mynatt, R. L. , Ravussin, E. , Stephens, J. M. , & Dixit, V. D. (2011). The NLRP3 inflammasome instigates obesity‐induced inflammation and insulin resistance. Nature Medicine, 17, 179–188.
- Wassef, H. , Bissonnette, S. , Saint‐Pierre, N. , Lamantia, V. , Cyr, Y. , Chretien, M. , & Faraj, M. (2015). The apoB/ PCSK9 ratio: a new index for metabolic risk in humans. Journal of Clinical Lipidology, 9, 664–675.
- Wassef, H. , Salem, H. , Bissonnette, S. , Baass, A. , Dufour, R. , Davignon, J. , & Faraj, M. (2012). White adipose tissue‐apoC‐I secretion; relation to delayed plasma clearance of dietary fat in humans. Arterioscler Throm Vasc Biol, 32, 2785–2793.
- Wen, H. , Gris, D. , Lei, Y. , Jha, S. , Zhang, L. , Huang, M.‐T.‐H. , Brickey, W. J. , & Ting, J.‐P.‐Y. (2011). Fatty acid‐induced NLRP3‐ASC inflammasome activation interferes with insulin signaling. Nature Immunology, 12, 408–415.
Source: PubMed